As reported by Northern Light Venture Capital, "Hongxing Xianghe" has recently declared the successful closure of its Pre-A round financing, raising nearly 100 million yuan. Northern Light Venture Capital took the lead in this funding round, with additional investments coming from Dongwei Fund, DCG Holdings, Dingfu Investment, and Future Venture Fund. Notably, Xingyao Taihao Fund, an angel-round investor, also opted to further increase its shareholding.

The capital raised in this round will be predominantly channeled into accelerating preclinical and clinical Proof of Concept (POC) studies for the company's existing drug development pipelines. Additionally, there will be a comprehensive integration of AI platforms and biological organoid technologies in drug discovery and assessment processes. The strategic objective is to cultivate core competencies in target identification and molecular druggability evaluation, molecular and experimental design, as well as multidimensional outcome assessment. This, in turn, is expected to streamline project initiation and decision-making processes, while also boosting the overall success rates of research and development endeavors.